FOR IMMEDIATE RELEASE
Contact: Jana Waterman, 541.912.6659
June 24, 2025
N E W S R E L E A S E
McKenzie-Willamette Medical Center First in Lane County to offer HYDROS™ Robotic System: A Cutting-Edge AI-Powered Platform for Aquablation Therapy to Treat BPH
SPRINGFIELD, OR—McKenzie-Willamette Medical Center today announced that it is the first in Lane County to offer Aquablation® therapy with the new HYDROS™ Robotic System, the next-generation platform to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Aquablation therapy, now delivered by an AI-powered robotic system, is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
BPH is an unfortunate reality of aging for millions of men and impacts urinary function, making it difficult to urinate and fully empty the bladder. Common indicators that a man may be experiencing BPH are the need to urinate immediately or urgently, urinating more often than normal and urinating frequently at night. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones and incontinence. One in two men ages 51-60 have BPH1 and 99 percent of men say BPH impacts their quality of life2. The standard treatment option today is surgery, but this has been shown to impact sexual function and continence.
Aquablation therapy was designed to offer a minimally invasive and effective solution for BPH, minimizing the need for men to choose between safety and efficacy. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets which prostate tissue to remove and which to preserve. With this tailored approach, the system accurately removes problematic tissue while safeguarding critical anatomy.
The clinically proven procedure integrates next-generation ultrasound imaging and digital cystoscopy to provide the surgeon with a multi-dimensional, detailed view of the entire prostate, enabling personalized treatment planning tailored to each patient’s unique anatomy. Utilizing a heat-free waterjet, the robot executes the surgeon-defined treatment plan to remove obstructive tissue while protecting critical anatomy. This enables efficient and predictable waterjet resection, standardizing the operative experience across a wide range of prostate sizes and shapes.
For more information on Aquablation therapy, visit aquablation.com.
Media Opportunity:
Wednesday, June 25th
10:30am
McKenzie-Willamette Medical Center, meet at main entrance
OR Photo Opportunity and Interview with Urologist
McKenzie-Willamette Medical Center is a 113-bed community hospital accredited by The Joint Commission. In 2018 a $115 million expansion and renovation project enhanced services offered to the community. With Level III Trauma Center accreditation, the emergency department maintains a 30-minutes-or-less service pledge. McKenzie-Willamette offers comprehensive services through McKenzie Heart, Lung and Vascular Center including cardiology and cardiovascular surgery. Key hospital services are obstetrics, general surgery, orthopedics, urology, radiology, rehabilitation, robotic surgery, telemedicine, and wound care. For more information, visit McKweb.com.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Its HYDROS™ Robotic System is the next-generation, AI-powered platform for Aquablation® therapy, a BPH treatment clinically proven to deliver significant, durable symptom relief while preserving sexual function and continence in prostates of all shapes and sizes. The Company has developed a significant and growing body of clinical evidence, including numerous clinical studies and peer-reviewed publications, that support the benefits and clinical advantages of Aquablation therapy.
1. Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3).
2. Data on file at PROCEPT BioRobotics.
Risk and Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence/perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention.
Rx Only
Please review the Instructions for Use and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.
© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, HYDROS, PROCEPT BioRobotics, and the PROCEPT BioRobotics logo are trademarks and/or registered trademarks of PROCEPT BioRobotics Corporation. ML0636.A